Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 11/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521883 | 0.88 | FGFR4 (0.46) | FGFR4MAPTLMNAGAAFGFR1 | |
| SCHEMBL1521723 | 0.85 | FGFR4 (0.66) | FGFR4LCKFGFR1FGFR2FGFR3 | |
| SCHEMBL1521396 | 0.84 | FGFR4 (0.52) | FGFR4LCKFGFR1FGFR3KDR | |
| SCHEMBL1521642 | 0.83 | FGFR4 (0.51) | FGFR4LCKFGFR1FGFR2FGFR3 | |
| SCHEMBL1521831 | 0.77 | MAPT (0.46) | FGFR4MAPTLMNAGAAFGFR1 | |
| SCHEMBL6620598 | 0.77 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL6618207 | 0.76 | FGFR4 (0.61) | FGFR4LCKFGFR1FGFR2FGFR3 | |
| SCHEMBL15412943 | 0.75 | FGFR4 (1.00) | FGFR4MAPTLMNAFGFR1FGFR2 | |
| SCHEMBL3573608 | 0.75 | FGFR4 (0.55) | FGFR4LCKLMNAFGFR1FGFR3 | |
| SCHEMBL1521496 | 0.74 | MAPT (0.42) | FGFR4MAPTLMNAGAAFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2063896-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008033999-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | FGFR4 1073/4885MAPT 1608/4885LCK 233/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | FGFR4 1073/4885MAPT 1608/4885LCK 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.